Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 9;5(6):586-596.
doi: 10.1002/mdc3.12673. eCollection 2018 Nov-Dec.

Imaging Markers of Progression in Parkinson's Disease

Antonio P Strafella  1   2   3 , Nico I Bohnen  4   5   6 , Nicola Pavese  7 , David E Vaillancourt  8 , Thilo van Eimeren  9   10   11 , Marios Politis  12 , Alessandro Tessitore  13 , Christine Ghadery  1   2   3 , Simon Lewis  14 ; IPMDS‐Neuroimaging Study Group
Affiliations
Review

Imaging Markers of Progression in Parkinson's Disease

Antonio P Strafella et al. Mov Disord Clin Pract. .

Abstract

Background: Parkinson's disease (PD) is the second-most common neurodegenerative disorder after Alzheimer's disease; however, to date, there is no approved treatment that stops or slows down disease progression. Over the past decades, neuroimaging studies, including molecular imaging and MRI are trying to provide insights into the mechanisms underlying PD.

Methods: This work utilized a literature review.

Results: It is now becoming clear that these imaging modalities can provide biomarkers that can objectively detect brain changes related to PD and monitor these changes as the disease progresses, and these biomarkers are required to establish a breakthrough in neuroprotective or disease-modifying therapeutics.

Conclusions: Here, we provide a review of recent observations deriving from PET, single-positron emission tomography, and MRI studies exploring PD and other parkinsonian disorders.

Keywords: Parkinson's disease; imaging biomarker; magnetic resonance imaging; molecular imaging.

PubMed Disclaimer

References

    1. Athauda D, Foltynie T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol 2015;11:25–40. - PubMed
    1. Olanow CW, Rascol O, Hauser R, et al. A double‐blind, delayed‐start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268–1278. - PubMed
    1. Politis M, Piccini P, Pavese N, Koh SB, Brooks DJ. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C‐raclopride PET study. Exp Neurol 2008;214:112–116. - PubMed
    1. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinsons disease. Ann Neurol 2000;47:493–503. - PubMed
    1. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single‐photon emission computed tomographic [123I]beta‐CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589–598. - PubMed